home / stock / mist / mist news


MIST News and Press, Milestone Pharmaceuticals Inc.

Stock Information

Company Name: Milestone Pharmaceuticals Inc.
Stock Symbol: MIST
Market: NASDAQ
Website: milestonepharma.com

Menu

Get MIST Alerts

News, Short Squeeze, Breakout and More Instantly...

MIST - Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST(TM) (etripamil) Nasal Spray in Patients With PSVT

MONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced details on RESET-PSVT, a planned Phase 4, mul...

MIST - Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the  25 ...

MIST - Milestone Pharmaceuticals Announces that CARDAMYST(TM) (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Express Scripts, one of the n...

MIST - Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

2026-03-20 18:32:16 ET Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call March 20, 2026 8:30 AM EDT... Read the full article on Seeking Alpha For further details see: Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

MIST - Milestone Pharmaceuticals GAAP EPS of -$0.75, revenue of $1.55M

2026-03-20 08:05:18 ET More on Milestone Pharmaceuticals Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense Seeking Alpha’s Quant Rating on Milestone Pharmaceutical...

MIST - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST(TM) (etripamil) Nasal Spray for the Treatment of PSVT

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT Participants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placebo CARDAMYST ...

MIST - Expected US Company Earnings on Friday, March 20th, 2026

Creative Medical Technology Holdings Inc. (CELZ) is expected to report $-0.37 for Q4 2025 Creative Realities Inc. (CREX) is expected to report $-0.07 for Q4 2025 BitFuFu Inc. (FUFU) is expected to report $-0.01 for Q4 2025 Moleculin Biotech Inc. (MBRX) is expected to report $-7.76 for...

MIST - Milestone Pharmaceuticals to Present Data on CARDAMYST(TM) (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated poster presentation titled ...

MIST - Milestone: Downgrading To Sell As CARDAMYST Faces A Tough Reality

2026-03-14 02:49:46 ET Overview My last analysis of Milestone Pharmaceuticals ( MIST ) immediately followed the FDA approval of CARDAMYST (etripamil), a calcium channel blocker administered intranasally to terminate PSVT in adults. I spent a lot of time talking about the alt...

MIST - Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement wil...

Next 10